InMed Pharmaceuticals Inc.
INM
$0.88
-$0.01-1.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -26.22% | -11.43% | 1.68% | 7.59% | -10.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.22% | -11.43% | 1.68% | 7.59% | -10.36% |
| Cost of Revenue | -2.27% | -7.03% | -10.88% | 22.98% | -28.96% |
| Gross Profit | -60.03% | -18.28% | 23.73% | -39.34% | 42.21% |
| SG&A Expenses | -5.68% | 2.61% | 27.93% | -3.28% | 26.01% |
| Depreciation & Amortization | 0.00% | -2.56% | -3.65% | -4.56% | -3.62% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.37% | -4.48% | -4.41% | 13.75% | 12.67% |
| Operating Income | 3.88% | -0.54% | 8.31% | -17.77% | -29.42% |
| Income Before Tax | 21.23% | -2.92% | 7.37% | -23.10% | -74.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.23% | -2.92% | 7.71% | -23.10% | -74.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.23% | -2.92% | 7.71% | -23.10% | -74.20% |
| EBIT | 3.88% | -0.54% | 8.31% | -17.77% | -29.42% |
| EBITDA | 3.98% | -0.64% | 8.43% | -18.47% | -30.52% |
| EPS Basic | 80.15% | 83.86% | 70.32% | 46.01% | 1.71% |
| Normalized Basic EPS | 80.15% | 83.86% | 70.21% | 46.01% | 1.71% |
| EPS Diluted | 80.15% | 83.86% | 70.32% | 46.01% | 1.71% |
| Normalized Diluted EPS | 80.15% | 83.86% | 70.21% | 46.01% | 1.71% |
| Average Basic Shares Outstanding | 296.91% | 537.72% | 210.94% | 128.05% | 77.20% |
| Average Diluted Shares Outstanding | 296.91% | 537.72% | 210.94% | 128.05% | 77.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |